Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants

Infection and Immunity

Volumn 78, Issue 1, 2010, Pages 400-412

  Ranallo, Ryan T ^a   Kaminski, Robert W ^a   George, Tonia ^a,b   Kordis, Alexis A ^a   Chen, Qing ^a,c   Szabo, Kathleen ^a,d   Venkatesan, Malabi M ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b BOEHRINGER INGELHEIM VETMEDICA INC   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; INTERLEUKIN 1BETA; LIPID A; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CELL DIVISION; CELL INVASION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DETOXIFICATION; EPITHELIUM CELL; FEMALE; GENE DELETION; GENETIC COMPLEMENTATION; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; MACROPHAGE; MOUSE; MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SHIGELLA FLEXNERI; VACCINATION;

ADAPTIVE IMMUNITY; ANIMALS; BACTERIAL PROTEINS; CYTOKINES; ENTEROBACTERIACEAE INFECTIONS; GENE EXPRESSION REGULATION, BACTERIAL; HELA CELLS; HUMANS; INFLAMMATION; LUNG; LUNG DISEASES; MICE; MUTATION; SHIGELLA FLEXNERI; SPLEEN; VIRULENCE;

EID: 73449131553     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00533-09     Document Type: Article

References (52)

1. Anisimov, A. P., R. Z. Shaikhutdinova, L. N. Pan'kina, V. A. Feodorova, E. P. Savostina, O. V. Bystrova, B. Lindner, A. N. Mokrievich, I. V. Bakhteeva, G. M. Titareva, S. V. Dentovskaya, N. A. Kocharova, S. N. Senchenkova, O. Holst, Z. L. Devdariani, Y. A. Popov, G. B. Pier, and Y. A. Knirel. 2007. Effect of deletion of the IpxM gene on virulence and vaccine potential of Yersinia pestis in mice. J. Med. Microbiol. 56:443-453.
2. Burland, V., Y. Shao, N. T. Perna, G. Plunkett, H. J. Sofia, and F. R. Blattner. 1998. The complete DNA sequence and analysis of the large virulence plasmid of Escherichia coli O157:H7. Nucleic Acids Res. 26:4196-4204.
3. Cersini, A., M. C. Martino, I. Martini, G. Rossi, and M. L. Bernardini. 2003. Analysis of virulence and inflammatory potential of Shigella flexneri purine biosynthesis mutants. Infect. Immun. 71:7002-7013.
4. Clements, A., D. Tull, A. W. Jenney, J. L. Farn, S. H. Kim, R. E. Bishop, J. B. McPhee, R. E. Hancock, E. L. Hartland, M. J. Pearse, O. L. Wijburg, D. C. Jackson, M. J. McConville, and R. A. Strugnell. 2007. Secondary acylation of Klebsiella pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptides. J. Biol. Chem. 282:15569-15577.
5. Clementz, T., J. J. Bednarski, and C. R. Raetz. 1996. Function of the htrB high temperature requirement gene of Escherichia coli in the acylation of lipid A: HtrB catalyzed incorporation of laurate. J. Biol. Chem. 271:12095-12102.
6. Clementz, T., Z. Zhou, and C. R. Raetz. 1997. Function of the Escherichia coli msbB gene, a multicopy suppressor of htrB knockouts, in the acylation of lipid A. Acylation by MsbB follows laurate incorporation by HtrB. J. Biol. Chem. 272:10353-10360.
7. Coats, S. R., C. T. Do, L. M. Karimi-Naser, P. H. Braham, and R. P. Darveau. 2007. Antagonistic lipopolysaccharides block E. coli lipopolysaccharide function at human TLR4 via interaction with the human MD-2 lipopolysaccharide binding site. Cell. Microbiol. 9:1191-1202.
8. Coster, T. S., C. W. Hoge, L. L. VanDeVerg, A. B. Hartman, E. V. Oaks, M. M. Venkatesan, D. Cohen, G. Robin, A. Fontaine-Thompson, P. J. Sansonetti, and T. L. Hale. 1999. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun. 67:3437-3443.
9. D'Hauteville, H., S. Khan, D. J. Maskell, A. Kussak, A. Weintraub, J. Mathison, R. J. Ulevitch, N. Wuscher, C. Parsot, and P. J. Sansonetti. 2002. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J. Immunol. 168:5240-5251.
10. DuPont, H. L., R. B. Hornick, A. T. Dawkins, M. J. Snyder, and S. B. Formal. 1969. The response of man to virulent Shigella flexneri 2a. J. Infect. Dis. 119:296-299.
11. Everest, P., J. Ketley, S. Hardy, G. Douce, S. Khan, J. Shea, D. Holden, D. Maskell, and G. Dougan. 1999. Evaluation of Salmonella typhimurium mutants in a model of experimental gastroenteritis. Infect. Immun. 67:2815-2821.
12. Fernandez-Prada, C. M., D. L. Hoover, B. D. Tall, A. B. Hartman, J. Kopelowitz, and M. M. Venkatesan. 2000. Shigella flexneri IpaH(7.8) facilitates escape of virulent bacteria from the endocytic vacuoles of mouse and human macrophages. Infect. Immun. 68:3608-3619.
13. Formal, S. B., E. V. Oaks, R. E. Olsen, M. Wingfield-Eggleston, P. J. Snoy, and J. P. Cogan. 1991. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J. Infect. Dis. 164:533-537.
14. Goldman, S. R., Y. Tu, and M. B. Goldberg. 2008. Differential regulation by magnesium of the two MsbB paralogs of Shigella flexneri. J. Bacteriol. 190:3526-3537.
15. Hajjar, A. M., R. K. Ernst, J. H. Tsai, C. B. Wilson, and S. I. Miller. 2002. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat. Immunol. 3:354-359.
16. Hartman, A. B., C. J. Powell, C. L. Schultz, E. V. Oaks, and K. H. Eckels. 1991. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infect. Immun. 59:4075-4083.
17. Hartman, A. B., and M. M. Venkatesan. 1998. Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Infect. Immun. 66:4572-4576.
18. Jensen, V. B., J. T. Harty, and B. D. Jones. 1998. Interactions of the invasive pathogens Salmonella typhimurium, Listeria monocytogenes, and Shigella flexneri with M cells and murine Peyer's patches. Infect. Immun. 66:3758-3766.
19. Jerala, R. 2007. Structural biology of the LPS recognition. Int. J. Med. Microbiol. 297:353-363.
20. Kalupahana, R., A. R. Emilianus, D. Maskell, and B. Blacklaws. 2003. Salmonella enterica serovar Typhimurium expressing mutant lipid A with decreased endotoxicity causes maturation of murine dendritic cells. Infect. Immun. 71:6132-6140.
21. Kaminski, R. W., K. R. Turbyfill, and E. V. Oaks. 2006. Mucosal adjuvant properties of the Shigella invasin complex. Infect. Immun. 74:2856-2866.
22. Karow, M., O. Fayet, A. Cegielska, T. Ziegelhoffer, and C. Georgopoulos. 1991. Isolation and characterization of the Escherichia coli htrB gene, whose product is essential for bacterial viability above 33 degrees C in rich media. J. Bacteriol. 173:741-750.
23. Khan, S. A., P. Everest, S. Servos, N. Foxwell, U. Zahringer, H. Brade, E. T. Rietschel, G. Dougan, I. G. Charles, and D. J. Maskell. 1998. A lethal role for lipid A in Salmonella infections. Mol. Microbiol. 29:571-579.
24. Kim, S. H., W. Jia, R. E. Bishop, and C. Gyles. 2004. An msbB homologue carried in plasmid pO157 encodes an acyltransferase involved in lipid A biosynthesis in Escherichia coli O157:H7. Infect. Immun. 72:1174-1180.
25. Liu, T., R. Konig, J. Sha, S. L. Agar, C. T. Tseng, G. R. Klimpel, and A. K. Chopra. 2008. Immunological responses against Salmonella enterica serovar Typhimurium Braun lipoprotein and lipid A mutant strains in Swiss-Webster mice: potential use as live-attenuated vaccines. Microb. Pathog. 44:224-237.
26. Mallett, C. P., L. VanDeVerg, H. H. Collins, and T. L. Hale. 1993. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model. Vaccine 11:190-196.
27. Mills, J. A., J. M. Buysse, and E. V. Oaks. 1988. Shigella flexneri invasion plasmid antigens B and C: epitope location and characterization with monoclonal antibodies. Infect. Immun. 56:2933-2941.
28. Murray, S. R., D. Bermudes, K. S. de Felipe, and K. B. Low. 2001. Extragenic suppressors of growth defects in msbB Salmonella. J. Bacteriol. 183:5554-5561.
29. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
30. Nonaka, T., T. Kuwabara, H. Mimuro, A. Kuwae, and S. Imajoh-Ohmi. 2003. Shigella-induced necrosis and apoptosis of U937 cells and J774 macrophages. Microbiology 149:2513-2527.
31. Oaks, E. V., M. E. Wingfield, and S. B. Formal. 1985. Plaque formation by virulent Shigella flexneri. Infect. Immun. 48:124-129.
32. Phalipon, A., and P. J. Sansonetti. 2007. Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival? Immunol. Cell Biol. 85:119-129.
33. Post, D. M., M. R. Ketterer, N. J. Phillips, B. W. Gibson, and M. A. Apicella. 2003. The msbB mutant of Neisseria meningitidis strain NMB has a defect in lipooligosaccharide assembly and transport to the outer membrane. Infect. Immun. 71:647-655.
34. Post, D. M., N. J. Phillips, J. Q. Shao, D. D. Entz, B. W. Gibson, and M. A. Apicella. 2002. Intracellular survival of Neisseria gonorrhoeae in male urethral epithelial cells: importance of a hexaacyl lipid A. Infect. Immun. 70: 909-920.
35. Ranallo, R. T., S. Barnoy, S. Thakkar, T. Urick, and M. M. Venkatesan. 2006. Developing live Shigella vaccines using lambda Red recombineering. FEMS Immunol. Med. Microbiol. 47:462-469.
36. Ranallo, R. T., S. Thakkar, Q. Chen, and M. M. Venkatesan. 2007. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. Vaccine 25:2269-2278.
37. Saito, T., T. Yamamoto, T. Kazawa, H. Gejyo, and M. Naito. 2005. Expression of toll-like receptor 2 and 4 in lipopolysaccharide-induced lung injury in mouse. Cell Tissue Res. 321:75-88.
38. Schroeder, G. N., and H. Hilbi. 2008. Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin. Microbiol. Rev. 21:134-156.
39. Schroeder, G. N., N. J. Jann, and H. Hilbi. 2007. Intracellular type III secretion by cytoplasmic Shigella flexneri promotes caspase-1-dependent macrophage cell death. Microbiology 153:2862-2876.
40. Somerville, J. E., Jr., L. Cassiano, B. Bainbridge, M. D. Cunningham, and R. P. Darveau. 1996. A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide. J. Clin. Investig. 97:359-365.
41. Somerville, J. E., Jr., L. Cassiano, and R. P. Darveau. 1999. Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infect. Immun. 67:6583-6590.
42. Suzuki, T., Y. Yoshikawa, H. Ashida, H. Iwai, T. Toyotome, H. Matsui, and C. Sasakawa. 2006. High vaccine efficacy against shigellosis of recombinant noninvasive Shigella mutant that expresses Yersinia invasin. J. Immunol. 177:4709-4717.
43. Toso, J. F., V. J. Gill, P. Hwu, F. M. Marincola, N. P. Restifo, D. J. Schwartzentruber, R. M. Sherry, S. L. Topalian, J. C. Yang, F. Stock, L. J. Freezer, K. E. Morton, C. Seipp, L. Haworth, S. Mavroukakis, D. White, S. Mac-Donald, J. Mao, M. Sznol, and S. A. Rosenberg. 2002. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 20:142-152.
44. Turbyfill, K. R., A. B. Hartman, and E. V. Oaks. 2000. Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine. Infect. Immun. 68:6624-6632.
45. van der Ley, P., L. Steeghs, H. J. Hamstra, J. ten Hove, B. Zomer, and L. van Alphen. 2001. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect. Immun. 69:5981-5990.
46. van de Verg, L. L., C. P. Mallett, H. H. Collins, T. Larsen, C. Hammack, and T. L. Hale. 1995. Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection. Infect. Immun. 63:1947-1954.
47. Venkatesan, M. M., M. B. Goldberg, D. J. Rose, E. J. Grotbeck, V. Burland, and F. R. Blattner. 2001. Complete DNA sequence and analysis of the large virulence plasmid of Shigella flexneri. Infect. Immun. 69:3271-3285.
48. Venkatesan, M. M., A. B. Hartman, J. W. Newland, V. S. Ivanova, T. L. Hale, M. McDonough, and J. Butterton. 2002. Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine. Infect. Immun. 70:2950-2958.
49. Venkatesan, M. M., and R. T. Ranallo. 2006. Live-attenuated Shigella vaccines. Expert Rev. Vaccines 5:669-686.
50. Watson, P. R., A. Benmore, S. A. Khan, P. W. Jones, D. J. Maskell, and T. S. Wallis. 2000. Mutation of waaN reduces Salmonella enterica serovar Typhimurium-induced enteritis and net secretion of type III secretion system 1-dependent proteins. Infect. Immun. 68:3768-3771.
51. Way, S. S., A. C. Borczuk, R. Dominitz, and M. B. Goldberg. 1998. An essential role for gamma interferon in innate resistance to Shigella flexneri infection. Infect. Immun. 66:1342-1348.
52. Way, S. S., A. C. Borczuk, and M. B. Goldberg. 1999. Thymic independence of adaptive immunity to the intracellular pathogen Shigella flexneri serotype 2a. Infect. Immun. 67:3970-3979.